Home LiteratureArticle Details
PMID: 3182080 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Membrane glycoprotein M-2 protects against Leishmania amazonensis infection.

Infection and immunity ·Vol. 56 ·No. 12 ·1988-12-00 ·Pages 3272-9

Champsi J, McMahon-Pratt D

Abstract

Previous passive antibody transfer experiments have indicated that immunity to a 46-kilodalton membrane glycoprotein (M-2) of Leishmania amazonensis may protect against infection with this parasite. In the studies described in this paper, we investigated the ability of the purified M-2 molecule to elicit a protective immune response in conjunction with Freund incomplete and complete adjuvants, saponin, and Corynebacterium parvum. Both relatively susceptible (BALB/c and CBA) and resistant (C57BL/6) strains of mice were examined. C. parvum appeared to be the most effective adjuvant in the three mouse strains tested. The level of protection varied with the mouse strain, although all animals received identical preparations of antigen and adjuvant. Immunization of CBA mice with the M-2 glycoprotein and C. parvum resulted in complete protection against a challenge infection of 10(4) and 10(6) late log-phase promastigotes of L. amazonensis. In the BALB/c strain, complete protection was observed in some of the immunized animals (28 to 50%); in the rest of the mice the onset of infection was significantly delayed. Protective immunity for C57BL/6 mice was observed only at the low infecting dose (10(4) L. amazonensis organisms). The level of protection observed is reflected by increased antibody response (immunoglobulins G1 and G2) developed to the M-2 molecule. The relationship of pure T-cell (nonantibody) immunity to this protection remains to be elucidated.

MeSH Terms
Adjuvants, Immunologic Animals Antibodies, Monoclonal/immunology Antibodies, Protozoan/immunology Antigens, Protozoan/immunology Blotting, Western Leishmania/immunology Leishmaniasis/prevention & control Membrane Glycoproteins/immunology Mice Mice, Inbred Strains Molecular Weight Saponins/administration & dosage Vaccination
Chemicals
Adjuvants, Immunologic Antibodies, Monoclonal Antibodies, Protozoan Antigens, Protozoan Membrane Glycoproteins Saponins
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Champsi J
Department of Epidemiology, Yale University School of Medicine, New Haven, Connecticut 06510.
McMahon-Pratt D
References (45)
45 references, click to expand
  1. B lymphocytes are required for the generation of T cells that mediate healing of cutaneous leishmaniasis.
    J Immunol. 1986 Aug 1;137(3):1017-21 PMID: 3487581
  2. DISSEMINATED CUTANEOUS LEISHMANIASIS; INNOCULATION TO LABORATORY ANIMALS, ELECTRON MICROSCOPY AND FLUORESCENT ANTIBODIES STUDIES.
    Arch Dermatol. 1965 May;91:439-47 PMID: 14275881
  3. Leishmania spp.: agar plating as an alternative to limiting dilution and impression smears for the enumeration of viable parasites in tissue.
    Exp Parasitol. 1987 Feb;63(1):108-11 PMID: 3803532
  4. Structural and antigenic characterization of a species- and promastigote-specific Leishmania mexicana amazonensis membrane protein.
    J Immunol. 1987 Mar 1;138(5):1587-95 PMID: 3543130
  5. Modulation of the pattern of development of experimental disseminated leishmaniasis by Corynebacterium parvum.
    J Leukoc Biol. 1987 Feb;41(2):165-9 PMID: 3468194
  6. Immunotherapy versus chemotherapy in localised cutaneous leishmaniasis.
    Lancet. 1987 Feb 21;1(8530):401-5 PMID: 2880213
  7. Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
    Nature. 1970 Aug 15;227(5259):680-5 PMID: 5432063
  8. Effect of Corynebacterium parvum on the class and subclass of antibody produced in the response of different strains of mice to sheep erythrocytes.
    Immunology. 1975 Mar;28(3):431-42 PMID: 1092609
  9. Leishmaniasis in Brazil: X. Some observations of intradermal reactions to different trypanosomatid antigens of patients suffering from cutaneous and mucocutaneous leishmaniasis.
    Trans R Soc Trop Med Hyg. 1975;69(3):323-35 PMID: 52214
  10. The adjuvant effect of Corynebacterium parvum: T-cell dependence of macrophage activation.
    J Exp Med. 1977 Jan 1;145(1):45-57 PMID: 299769
  11. Leishmaniasis in Brazil: XII. Observations on cross-immunity in monkeys and man infected with Leishmania mexicana mexicana, L. m. amazonensis, L. braziliensis braziliensis, L. b. guyanensis and L. b. panamensis.
    J Trop Med Hyg. 1977 Feb;80(2):29-35 PMID: 405504
  12. Effects of repeated Corynebacterium parvum and BCG therapy on immune parameters: a weekly sequential study of melanoma patients. I. Changes in non-specific (NK, K and T cell) lymphocytotoxicity, peripheral blood counts and delayed hypersensitivity reactions.
    Clin Exp Immunol. 1979 May;36(2):227-36 PMID: 314367
  13. Protective immunisation of mice using cell surface glycoprotein from Trypanosoma cruzi.
    Nature. 1979 Nov 1;282(5734):73-4 PMID: 116128
  14. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.
    Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350-4 PMID: 388439
  15. Nor-MDP, saponin, corynebacteria, and pertussis organisms as immunological adjuvants in experimental malaria vaccination of macaques.
    Bull World Health Organ. 1979;57 Suppl 1:189-97 PMID: 232428
  16. Human cutaneous lieshmania in a mouse macrophage line: propagation and isolation of intracellular parasites.
    Science. 1980 Sep 12;209(4462):1240-42 PMID: 7403880
  17. The present and future of vaccination for cutaneous leishmaniasis.
    Prog Clin Biol Res. 1980;47:259-85 PMID: 7010374
  18. Monoclonal antibodies that distinguish between New World species of Leishmania.
    Nature. 1981 Jun 18;291(5816):581-3 PMID: 6787433
  19. Elimination of Leishmania donovani amastigotes by activated macrophages.
    Infect Immun. 1981 Sep;33(3):918-26 PMID: 7287190
  20. Specific inhibition of lymphocyte-proliferation responses by adherent suppressor cells in diffuse cutaneous leishmaniasis.
    N Engl J Med. 1982 Feb 18;306(7):387-92 PMID: 6460184
  21. A comparison of saponin with other adjuvants for the potentiation of protective immunity by a killed Plasmodium yoelii vaccine in the mouse.
    Parasite Immunol. 1982 Sep;4(5):337-47 PMID: 7145465
  22. Monoclonal antibodies recognizing determinants specific for the promastigote state of Leishmania mexicana.
    Mol Biochem Parasitol. 1982 Nov;6(5):317-27 PMID: 7177168
  23. Leishmaniasis in beige mice.
    Infect Immun. 1982 Dec;38(3):1208-16 PMID: 6218091
  24. Late metastatic Leishmaniasis in the mouse. A model for mucocutaneous disease.
    Am J Trop Med Hyg. 1983 Mar;32(2):277-85 PMID: 6837839
  25. Advantages of measuring changes in the number of viable parasites in murine models of experimental cutaneous leishmaniasis.
    Infect Immun. 1983 Mar;39(3):1087-94 PMID: 6840835
  26. Resistance to macrophage-mediated killing as a factor influencing the pathogenesis of chronic cutaneous leishmaniasis.
    J Immunol. 1983 Aug;131(2):966-71 PMID: 6863939
  27. Leishmania tropica major in mice: vaccination against cutaneous leishmaniasis in mice of high genetic susceptibility.
    Aust J Exp Biol Med Sci. 1983 Feb;61(Pt 1):11-25 PMID: 6870673
  28. In vivo protection against Leishmania mexicana mediated by monoclonal antibodies.
    J Immunol. 1983 Oct;131(4):1616-8 PMID: 6619540
  29. Prophylactic immunization against experimental leishmaniasis. II. Further characterization of the protective immunity against fatal Leishmania tropica infection induced by irradiated promastigotes.
    J Immunol. 1984 Jan;132(1):450-5 PMID: 6197456
  30. Prophylactic immunization against experimental leishmaniasis. III. Protection against fatal Leishmania tropica infection induced by irradiated promastigotes involves Lyt-1+2- T cells that do not mediate cutaneous DTH.
    J Immunol. 1984 Jan;132(1):456-61 PMID: 6228580
  31. The American leishmaniases: some observations on their ecology and epidemiology.
    Trans R Soc Trop Med Hyg. 1983;77(5):569-96 PMID: 6197791
  32. Cutaneous leishmaniasis in anti-IgM-treated mice: enhanced resistance due to functional depletion of a B cell-dependent T cell involved in the suppressor pathway.
    J Immunol. 1984 Apr;132(4):2072-7 PMID: 6230400
  33. Production and characterization of species-specific monoclonal antibodies against Leishmania donovani for immunodiagnosis.
    J Immunol. 1984 Jul;133(1):440-7 PMID: 6373932
  34. An amphipathic sulphated glycoconjugate of Leishmania: characterization with monoclonal antibodies.
    EMBO J. 1984 Oct;3(10):2301-6 PMID: 6499830
  35. An experimental vaccine against American dermal leishmaniasis: experience in the State of Espírito Santo, Brazil.
    Ann Trop Med Parasitol. 1985 Jun;79(3):259-69 PMID: 4026438
  36. Immunization with Leishmania receptor for macrophages protects mice against cutaneous leishmaniasis.
    Proc Natl Acad Sci U S A. 1985 Sep;82(17):5910-4 PMID: 3862105
  37. A limiting dilution assay for quantifying Leishmania major in tissues of infected mice.
    Parasite Immunol. 1985 Sep;7(5):545-55 PMID: 3877902
  38. Characterization of cellular immune response to chemically defined glycoconjugates from Leishmania mexicana subsp. amazonensis.
    Infect Immun. 1986 Jan;51(1):80-6 PMID: 2416692
  39. Cutaneous leishmaniasis. The defect in T cell influx in BALB/c mice.
    J Exp Med. 1987 Feb 1;165(2):546-59 PMID: 3546576
  40. Identification and distribution of New World Leishmania species characterized by serodeme analysis using monoclonal antibodies.
    Am J Trop Med Hyg. 1987 Mar;36(2):270-87 PMID: 3826486
  41. The correlation between delayed hypersensitivity, lymphocyte activation and protective immunity in experimental murine leishmaniasis.
    Parasite Immunol. 1987 Jan;9(1):105-15 PMID: 3562057
  42. Vaccination against cutaneous leishmaniasis in a murine model. I. Induction of protective immunity with a soluble extract of promastigotes.
    J Immunol. 1987 Jul 1;139(1):221-7 PMID: 3495599
  43. Effective immunization against cutaneous leishmaniasis with defined membrane antigens reconstituted into liposomes.
    J Immunol. 1988 Feb 15;140(4):1274-9 PMID: 3257774
  44. IMMUNITY TO LEISHMANIA MEXICANA FOLLOWING SPONTANEOUS RECOVERY FROM ORIENTAL SORE.
    Trans R Soc Trop Med Hyg. 1964 May;58:274-7 PMID: 14160915
  45. Inhibition in vivo of both infective Leishmania major and L. mexicana amazonensis mediated by a single monoclonal antibody.
    Trans R Soc Trop Med Hyg. 1986;80(2):258-60 PMID: 3787687
Article Info
Journal
Infection and immunity
Abbr.
Infect Immun
ISSN
0019-9567
DOI
10.1128/iai.56.12.3272-3279.1988
Published
1988-12-00
Pages
3272-9
Language
English
Region
United States
NLM ID
0246127
PMCID
PMC259734
Subset
IM
Grants
NIAID NIH HHS · AI-23004 · United States
NHLBI NIH HHS · T-35HL7479 · United States
External Links
PubMed source DOI: 10.1128/iai.56.12.3272-3279.1988 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2